Informations générales (source: ClinicalTrials.gov)
Effect of Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation
Interventional
Phase 3
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
juin 2024
juin 2026
03 décembre 2025
Liver transplantation (LT) is a high-risk surgery for hemodynamic instability and
haemorrhagic shock with a high-risk of acute kidney injury (AKI). Indeed, the incidence
of post-transplant AKI exceeds 50% in some series with 15% of patients requiring renal
replacement therapy. Acute kidney injury after LT is a predisposing factor for chronic
renal failure which is independently associated with higher morbidity and mortality.
Arginine vasopressin (AVP), an essential stress hormone released in response to
hypotension, binds to AVPR1a to promote vasoconstriction. Furthermore, it may have
nephroprotective effects with a preferential vasoconstriction of the post-glomerular
arteriole resulting in increased glomerular filtration
The hypothesis of the present work is that low-dose arginine-vasopressin supplementation
reduce posttransplant AKI in liver transplantation.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP Assistance publique - Hôpitaux de Paris | 13/12/2025 07:38:11 | Contacter | |||
| AP-HP - Hôpital Beaujon | |||||
| AP-HP - Hôpital La Pitié-Salpêtrière | |||||
| AP-HP - Hôpital Paul Brousse | |||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| URC Lariboisière-Fernand Widal-saint Louis - 75010 - Paris - France | Nabila PIZZI | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Age ≥ 18 years
- Any adult patient with a scheduled liver transplantation
- All participants will need to be given clear information about the study and give
signed informed consent.
- Person affiliated to the Social Security
- Age ≥ 18 years
- Any adult patient with a scheduled liver transplantation
- All participants will need to be given clear information about the study and give
signed informed consent.
- Person affiliated to the Social Security
- Super-emergency for liver transplantation or fulminant hepatitis
- Patient listed for or receiving simultaneous liver-kidney transplantation (SLKT)
- Patients with end-stage renal disease (chronic eGFR < 15 mL/min/1.73 m2 or requiring
extra-renal purification before liver transplantation
- Patient with epilepsy
- Hypersensitivity to arginine-vasopressin and to its excipients
- Patient refusal
- Patients for whom it is impossible to give informed consent (language barrier)
- Adults under guardianship or trusteeship, persons deprived of their liberty
- Patient enrolled in another interventional clinical study
- Pregnancy or breastfeeding